Adaptive Biotechnologies Corporation (ADPT) Financial Ratios
8 years of historical data (2017–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
30Y Low19.2·High19.2
P/B Ratio
↓
11.94
↑+130% vs avg
5yr avg: 5.19
30Y Low2.3·High10.4
ROE
↓
-62.5%
↑-48% vs avg
5yr avg: -42.3%
30Y Low-62%·High-22%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Adaptive Biotechnologies Corporation currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.5B | $883M | $707M | $1.1B | $3.9B | $7.8B | $3.7B | — | — |
| Enterprise Value | $2.5B | $924M | $741M | $1.1B | $3.9B | $7.7B | $3.7B | — | — |
| P/E Ratio → | -15.22 | — | — | — | — | — | — | — | — |
| P/S Ratio | 14.02 | 4.93 | 4.15 | 5.88 | 25.52 | 78.86 | 43.73 | — | — |
| P/B Ratio | 11.94 | 4.36 | 2.29 | 2.35 | 6.52 | 10.44 | 6.51 | — | — |
| P/FCF | — | — | — | — | — | — | 19.16 | — | — |
| P/OCF | — | — | — | — | — | — | 18.11 | — | — |
P/E links to full P/E history page with 30-year chart
EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 5.16 | 4.35 | 5.97 | 25.34 | 78.71 | 43.03 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | 18.85 | — | — |
Profitability
Margins and return-on-capital ratios measuring operating efficiency
Adaptive Biotechnologies Corporation earns an operating margin of -90.8%. Operating margins have expanded from -108.0% to -90.8% over the past 3 years, signaling improving operational efficiency. A negative ROE of -62.5% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 59.7% | 59.7% | 55.6% | 68.7% | 68.1% | 77.1% | 73.8% | 64.7% | 59.2% |
| Operating Margin | -90.8% | -90.8% | -133.3% | -108.0% | -135.4% | -155.3% | -92.1% | -89.4% | -115.7% |
| Net Profit Margin | -89.1% | -89.1% | -132.3% | -108.0% | -134.3% | -148.6% | -80.6% | -83.4% | -111.4% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -62.5% | -62.5% | -58.3% | -37.5% | -30.8% | -22.3% | -43.8% | — | — |
| ROA | -26.6% | -26.6% | -29.7% | -22.5% | -20.3% | -14.4% | -11.0% | -13.4% | -11.8% |
| ROIC | -41.6% | -41.6% | -41.3% | -28.4% | -24.0% | -18.5% | -15.5% | -14.9% | — |
| ROCE | -32.0% | -32.0% | -34.4% | -25.7% | -23.0% | -16.6% | -13.7% | -15.3% | -13.0% |
Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $41M ($89M total debt minus $48M cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.44 | 0.44 | 0.32 | 0.23 | 0.18 | 0.15 | 0.06 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.20 | 0.11 | 0.04 | -0.05 | -0.02 | -0.11 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | -0.31 | — | — |
| Interest Coverage | -14.04 | -14.04 | -16.45 | -47.24 | — | — | — | — | — |
Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Adaptive Biotechnologies Corporation's current ratio of 2.89x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 5.12x to 2.89x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.89 | 2.89 | 4.66 | 5.12 | 3.54 | 6.91 | 7.82 | 7.93 | 9.77 |
| Quick Ratio | 2.81 | 2.81 | 4.50 | 4.99 | 3.37 | 6.78 | 7.71 | 7.58 | 9.54 |
| Cash Ratio | 2.27 | 2.27 | 3.94 | 4.54 | 3.10 | 6.54 | 7.37 | 7.24 | 9.15 |
| Asset Turnover | — | 0.33 | 0.26 | 0.22 | 0.17 | 0.09 | 0.09 | 0.17 | 0.11 |
| Inventory Turnover | 8.54 | 8.54 | 5.23 | 4.01 | 2.56 | 1.60 | 2.46 | 2.51 | 3.27 |
| Days Sales Outstanding | — | 85.11 | 81.39 | 78.90 | 41.17 | 37.27 | 54.39 | 31.52 | 52.99 |
Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Adaptive Biotechnologies Corporation does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | 5.2% | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $147M | $144M | $143M | $140M | $131M | $124M | $105M | $105M |
Peer Comparison
Compare ADPT with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ADPTYou | $3B | -15.2 | — | — | 59.7% | -90.8% | -62.5% | -41.6% | — |
 CAI | $33B | -6.2 | 718.4 | 496.4 | — | 5.6% | -93.2% | — | 0.0 |
 VCYT | $3B | 44.2 | 44.2 | 22.7 | 70.1% | 11.2% | 5.3% | 4.4% | 0.7 |
 NAUT | $331M | -5.6 | — | — | — | — | -32.3% | — | — |
 CDIO | $141M | -0.6 | — | — | 100.0% | -23977.9% | -134.0% | -222.7% | — |
 SEER | $103M | -1.3 | — | — | 49.0% | -717.7% | -23.9% | -21.3% | — |
 IMDX | $95M | -1.2 | — | — | 39.3% | -3245.1% | -1480.7% | — | — |
 ASBP | $63M | -5.1 | — | — | — | — | — | — | — |
 YDES | $35M | -15.1 | — | — | 30.4% | -286.5% | -42.7% | -63.3% | — |
 AIMD | $7M | -1.0 | — | — | -153.7% | -66772.2% | -74.4% | -39.8% | — |
 VRAX | $2M | -0.1 | — | — | -838.2% | -97344.8% | -114.4% | -273.2% | — |
| Healthcare Median | — | 23.2 | 14.9 | 19.0 | 65.8% | -6.4% | -36.7% | -13.6% | 3.0 |
Peers based on L4 peer group classification. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
See ADPT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ADPT Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare ADPT vs CAI
See how ADPT stacks up against sector leader Caris Life Sciences, Inc..
Start ComparisonFrequently Asked Questions
What is Adaptive Biotechnologies Corporation's P/E ratio?
Adaptive Biotechnologies Corporation's current P/E ratio is -15.2x. This places it at the 50th percentile of its historical range.
What is Adaptive Biotechnologies Corporation's ROE?
Adaptive Biotechnologies Corporation's return on equity (ROE) is -62.5%. The historical average is -42.5%.
Is ADPT stock overvalued?
Based on historical data, Adaptive Biotechnologies Corporation is trading at a P/E of -15.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Adaptive Biotechnologies Corporation's profit margins?
Adaptive Biotechnologies Corporation has 59.7% gross margin and -90.8% operating margin.